Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 11/20 | 0.71 |
| ▸ | GAA | P10253 | 6/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.71 |
| ▸ | MEN1 | O00255 | 10/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | CASP7 | P55210 | 1/20 | 0.59 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035961 | 0.87 | BPTF (0.78) | BPTFMAPTGAAKDM4EMEN1 | |
| SCHEMBL13366491 | 0.84 | BPTF (0.72) | BPTFMAPTGAAKDM4EMEN1 | |
| SCHEMBL2960241 | 0.84 | BPTF (0.72) | BPTFMAPTGAAKDM4EMEN1 | |
| SCHEMBL3347382 | 0.83 | MAPT (1.00) | BPTFMAPTGAAKDM4EMEN1 | |
| SCHEMBL2643671 | 0.82 | MAPT (0.73) | BPTFMAPTGAAKDM4EMEN1 | |
| SCHEMBL2960524 | 0.82 | BPTF (0.70) | BPTFMAPTGAAKDM4EMEN1 | |
| SCHEMBL2969418 | 0.82 | BPTF (0.69) | BPTFMAPTGAAKDM4EMEN1 | |
| SCHEMBL2963988 | 0.80 | MAPT (0.67) | BPTFMAPTGAAKDM4EMEN1 | |
| SCHEMBL7718443 | 0.78 | MAPT (0.67) | BPTFMAPTGAAKDM4EMEN1 | |
| SCHEMBL10856568 | 0.77 | ADORA1 (0.69) | BPTFMAPTGAAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714134-B2 | Compounds and use of tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714134-B2 | Compounds and use of tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714134-B2 | Compounds and use of tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090209534-A1 | NOVEL COMPOUNDS AND USE OF TETRAHYDROPYRIDOPYRIDOTHIOPHENES | PEKARI KLAUS | 2009-08-20 | — | — | US | disclosed |
| US-20090209534-A1 | NOVEL COMPOUNDS AND USE OF TETRAHYDROPYRIDOPYRIDOTHIOPHENES | PEKARI KLAUS | 2009-08-20 | — | — | US | disclosed |
| US-20090209534-A1 | NOVEL COMPOUNDS AND USE OF TETRAHYDROPYRIDOPYRIDOTHIOPHENES | PEKARI KLAUS | 2009-08-20 | — | — | US | disclosed |
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | PEKARI KLAUS | 2009-06-25 | — | — | US | disclosed |
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | PEKARI KLAUS | 2009-06-25 | — | — | US | disclosed |
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | PEKARI KLAUS | 2009-06-25 | — | — | US | disclosed |
| US-7517986-B2 | Tetrahydropyridothiophenes for use in the treatment of cancer | 4SC AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-20070259911-A1 | Novel Compounds and Use of Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259911-A1 | Novel Compounds and Use of Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| EP-1758655-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR TREATING HYPERPROLIFERATIVE DISORDERS | Altana Pharma AG (DE) | 2007-03-07 | — | — | EP | disclosed |
| EP-1756118-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Altana Pharma AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005120642-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR TREATING HYPERPROLIFERATIVE DISORDERS | ALTANA PHARMA AG (DE) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005118592-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | ALTANA PHARMA AG (DE) | 2005-12-15 | — | — | WO | disclosed |
| WO-1993013104-A1 | C.N.S. ACTIVE TRICYCLIC THIENOPYRIDINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209534-A1 | NOVEL COMPOUNDS AND USE OF TETRAHYDROPYRIDOPYRIDOTHIOPHENES | RB1, MCL1, CCAR2 | BPTF 142/4885MAPT 1694/4885GAA 4350/4885 |
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | BCL2, BAX, MCL1 | BPTF 424/4885MAPT 1411/4885GAA 3779/4885 |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | BCL2, BAX, MCL1 | BPTF 529/4885MAPT 1402/4885GAA 3762/4885 |
| US-20070259911-A1 | Novel Compounds and Use of Tetrahydropyridothiophenes | RB1, BAX, BCL2 | BPTF 137/4885MAPT 2055/4885GAA 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.